Lakewood-Amedex Reports Positive Preclinical Data for Bisphosphocin

The study focused on the intravesical administration of the compound Nu-8, which successfully combated bacterial growth where vehicle control groups showed no effect. Beyond urinary tract applications, the Bisphosphocin class demonstrated in vivo efficacy against pulmonary infections in animal models, specifically targeting Acinetobacter species, P. aeruginosa, and A. fumigatus. These pathogens are frequent drivers of hospital-acquired and ventilator-associated pneumonia.

CEO Kelvin Cooper emphasized the potential of the platform to address the global antimicrobial resistance (AMR) crisis, citing the compounds' rapid action and lack of expected resistance development. The company is currently evaluating the lead candidate, Nu-3, in a Phase 2a trial for diabetic foot ulcers, with initial results slated for release in the first quarter of 2027. Researchers continue to screen candidates from the Bisphosphocin family to determine which will proceed into early clinical development for respiratory and urological indications.